全文获取类型
收费全文 | 5722篇 |
免费 | 329篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 167篇 |
妇产科学 | 123篇 |
基础医学 | 853篇 |
口腔科学 | 32篇 |
临床医学 | 502篇 |
内科学 | 1462篇 |
皮肤病学 | 112篇 |
神经病学 | 721篇 |
特种医学 | 112篇 |
外科学 | 429篇 |
综合类 | 10篇 |
一般理论 | 1篇 |
预防医学 | 293篇 |
眼科学 | 48篇 |
药学 | 446篇 |
中国医学 | 13篇 |
肿瘤学 | 739篇 |
出版年
2024年 | 1篇 |
2023年 | 38篇 |
2022年 | 102篇 |
2021年 | 143篇 |
2020年 | 87篇 |
2019年 | 118篇 |
2018年 | 134篇 |
2017年 | 113篇 |
2016年 | 144篇 |
2015年 | 158篇 |
2014年 | 200篇 |
2013年 | 267篇 |
2012年 | 420篇 |
2011年 | 442篇 |
2010年 | 258篇 |
2009年 | 236篇 |
2008年 | 406篇 |
2007年 | 388篇 |
2006年 | 387篇 |
2005年 | 385篇 |
2004年 | 393篇 |
2003年 | 328篇 |
2002年 | 289篇 |
2001年 | 46篇 |
2000年 | 37篇 |
1999年 | 55篇 |
1998年 | 77篇 |
1997年 | 67篇 |
1996年 | 52篇 |
1995年 | 50篇 |
1994年 | 42篇 |
1993年 | 37篇 |
1992年 | 25篇 |
1991年 | 29篇 |
1990年 | 20篇 |
1989年 | 18篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 7篇 |
1985年 | 13篇 |
1984年 | 15篇 |
1983年 | 11篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 10篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1966年 | 1篇 |
1925年 | 1篇 |
1923年 | 1篇 |
排序方式: 共有6094条查询结果,搜索用时 31 毫秒
101.
102.
103.
Busca A Lovisone E Aliberti S Locatelli F Serra A Scaravaglio P Omedè P Rossi G Cirillo D Barbui A Ghisetti V Dall'Omo AM Falda M 《Hematology (Amsterdam, Netherlands)》2003,8(5):303-311
Non-myeloablative stem cell transplantation (NMT) has been increasingly used in compromised patients who would otherwise have been unable to undergo allotransplant. There is little understanding of the kinetics of immune reconstitution and its influence on infective complications following NMT. The aim of present study was to evaluate lymphocyte subset reconstitution over the first 12 months post-transplant in 15 adult patients receiving NMT with comparison to that of 30 patients grafted with a conventional hemopoietic stem cell transplantation (HSCT). NMT recipients were conditioned with fludarabine-based conditioning regimens. Peripheral blood stem cell (PBSC) was the source of stem cells in 13 NMT recipients and in 24 conventional HSCT recipients. Absolute numbers of helper (CD4+) T cells, naive (CD4+ CD45RA+) and memory (CD4+ CD45RO+) T cells as well as suppressor (CD8+) T cells, CD19+ B cells and NK cells were comparable in the two groups at all time points after transplantation. A median value of 200 CD4+ T cells/microl was achieved at 2 months post-transplant by the NMT and HSCT recipients. The CD4:CD8 ratio remained severely depressed throughout the study period. Almost all CD4+ lymphocytes expressed CD45RO antigen in the both groups of patients B lymphocytes showed low counts throughout the entire study period in both groups. Bacteremia and CMV antigenemia occurred respectively in 13 and 36% of the patients in the NMT group and in 15 and 39% of the patients in the HSCT group. Our preliminary data indicate that patients receiving a NMT have a lymphocyte reconstitution similar to that observed in patients who received a conventional HSCT. The incidence of bacteremia and CMV infection were not significantly different between the groups. Nevertheless, due to the small sample size, these results should be considered suggestive rather than definitive. 相似文献
104.
Rebecca De Lorenzo Clara Sciorati Antonella Monno Silvia Cavalli Francesco Bonomi Stefano Tronci Stefano Previtali Patrizia Rovere-Querini 《Medicine》2021,100(9)
Rationale:Severe refractory idiopathic inflammatory myopathy (IIM) represents a challenge for the clinician. The lack of efficacy of available tools reflects our incomplete insight into the molecular events sustaining the inflammatory tissue damage in these patients. We present the first case of refractory IIM treated with anti-dipeptidyl peptidase-4 (DPP-4)/cluster of differentiation 26 (CD26) monoclonal antibody.Patient concerns:A 55-year old man presented with proximal muscle weakness, diffuse erythematous skin lesions which rapidly evolved into ulcerations, dysphagia and dysphonia.Diagnosis:Increased serum creatine kinase levels and histological findings at muscle and skin biopsies were compatible with the diagnosis of dermatomyositis (DM). Several lines of treatment failed to control the disease including steroids, mycophenolate mofetil, tacrolimus, intravenous immunoglobulins and rituximab. Despite therapy, the patient also had recurrent intestinal vasculitis causing bowel perforation. Concurrently, DPP-4/CD26 expression in the patient''s skin and skeletal muscle was observed.Interventions:The patient was treated with begelomab, a murine immunoglobulin G2b monoclonal antibody against DPP-4/CD26.Outcomes:Dysphagia, skin lesions and intestinal vasculitis resolved and the patient experienced a significant improvement of his quality of life.Conclusion:Blockade of DPP-4/CD26, which is expressed on T cells and mediates T cell activation and function, is safe and might be effective in patients with refractory DM. 相似文献
105.
106.
107.
Borsi L Balza E Carnemolla B Sassi F Castellani P Berndt A Kosmehl H Biro A Siri A Orecchia P Grassi J Neri D Zardi L 《Blood》2003,102(13):4384-4392
We sought to enhance the selective toxicity of tumor necrosis factor alpha (TNFalpha) to permit its systemic use in cancer therapy. Because ligand-targeted therapeutics have proven successful in improving the selective toxicity of drugs, we prepared a fusion protein (L19mTNFalpha) composed of mouse TNFalpha and a high-affinity antibody fragment (L19 scFv) to the extradomain B (ED-B) domain of fibronectin, a marker of angiogenesis. L19mTNFalpha was expressed in mammalian cells, purified, and characterized. L19mTNFalpha was an immunoreactive and biologically active homotrimer. Radiolabeled L19mTNFalpha selectively targeted tumor neovasculature in tumor-bearing mice, where it accumulated selectively and persistently (tumor-to-blood ratio of the percentage of injected dose per gram [%ID/g] of 700, 48 hours from injection). L19mTNFalpha showed a greater anticancer therapeutic activity than both mTNFalpha and TN11mTNFalpha, a control fusion protein in which an antibody fragment, irrelevant in the tumor model used, substituted for L19. This activity was further dramatically enhanced by its combination with melphalan or the recently reported fusion protein L19-IL2. In conclusion, L19mTNFalpha allows concentrating therapeutically active doses of TNFalpha at the tumor level, thus opening new possibilities for the systemic use of TNFalpha in cancer therapy. 相似文献
108.
109.
Claudio Ponticelli MD Patrizia Passerini Donata Cresseri 《Geriatric Nephrology and Urology》1996,6(2):105-112
Recent studies have pointed out that the incidence of primary glomerular diseases is similar in the elderly and in younger populations. However the clinical characteristics of the different subtypes may be different in the advanced age. Minimal change nephropathy responds favorably to corticosteroids and/or cyclophosphamide, but many untreated or non-responder patients progress to end-stage renal disease or die from nephrotic complications. Focal and segmental glomerulosclerosis also has a severe prognosis in older patients but some 50% of patients may attain remission of the nephrotic syndrome with a prolonged corticosteroid treatment. The responders tend to maintain normal renal function over time. Membranoproliferative glomerulonephritis and IgA nephritis have a severe prognosis and do not respond to treatment. The clinical presentation and the outcome of membranous nephropathy are similar in the elderly and in younger adults. Corticosteroids are of little benefit while a 6-month treatment with chlorambucil and methylprednisolone may obtain remission of the nephrotic syndrome in about 2/3 of older patients. Crescentic glomerulonephritis has an ominous prognosis in older patients but some patients may improve if treatment with methylprednisolone pulses is started early. Acute postinfectious glomerulonephritis is often associated with renal failure in older patients. The prognosis may be severe. 相似文献
110.
Monica Terenziani MD Paolo D'Angelo MD Alessandro Inserra MD Renata Boldrini MD Gianni Bisogno MD Gian Luca Babbo MD Massimo Conte MD Patrizia Dall' Igna MD Maria Debora De Pasquale MD Paolo Indolfi MD Luigi Piva MD Giovanna Riccipetitoni MD Fortunato Siracusa MD Filippo Spreafico MD Paolo Tamaro MD Giovanni Cecchetto MD 《Pediatric blood & cancer》2015,62(7):1202-1208